PATENT CLAIM ANALYSIS

Application Number: 16265109
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-05
Patent Classification: ["514", "428000"]

Abstract:
The disclosure provides methods for treating estrogen receptor positive (ER + ) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER +  cancers.

Claim (Index 3):
The method of  claim 1 , wherein the patient has previously been treated with one or two prior lines of endocrine therapy, and wherein at least one of the prior lines of endocrine therapy is treatment with an aromatase inhibitor.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 99.0
- Lexical Diversity: 1.28
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15939218', '16475980', '14645578', '14753397', '15129197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7465957457060232
- 35 USC 102 Novelty (BERT): 0.5822036838004369
- Combined Prediction Score: 0.7301565395154646
- Mean Citation Score: 323.4696600000001
- Max Citation Score: 491.87918
- Similarity Product: 368.62101036057953

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test